Valuation dashboard for Quoin Pharmaceuticals, Ltd. (QNRX) with P/E N/A, P/B 3.58, EV/EBITDA -0.57 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Quoin Pharmaceuticals, Ltd. operates as a specialized pharmaceutical firm, concentrating its efforts on devising therapeutic solutions for rare and orphan medical conditions. Its flagship offering, QRX003, is a topical lotion specifically formulated to address Netherton Syndrome. Furthermore, the company is advancing QRX004 for the management of dystrophic epidermolysis bullosa, alongside QRX006, a prospective therapy for an additional rare dermatological ailment.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At the current price of $7.01, QNRX has negative trailing earnings (P/E not meaningful) and an ROE of -304.87%. Market capitalisation stands at $14M.
Balance sheet quality for QNRX: current ratio of 3.6. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 3.58 |
| EV / EBITDA | -0.57 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $2547.50 |
| vs Current Price | +36240.9% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| QNRX | Quoin Pharmaceuticals, Ltd. | $14M | 3.58 | -304.9% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.3B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $131.0B | 29.86 | 6.49 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.6B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $81.3B | 19.15 | 2.61 | 13.8% |
| MRNA | Moderna, Inc. | $62.7B | 1.46 | -39.2% | |
| ARGX | argenx SE | $61.9B | 36.71 | 7.48 | 21.7% |
| RVMD | Revolution Medicines, Inc. | $41.9B | 16.04 | -96.4% |
Price
| Price | $7.01 |
| Market Cap | $14M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -304.87% |
| Return on Invested Capital | -359.18% |
| Return on Assets | -156.71% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: CYCN · KTTA · NBY · PLRZ · PMCB · RADX · TCRT
Explore sector: Healthcare · Biotechnology
More sections of QNRX: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks